Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ:ATRC)

32.71 +0.45 (+1.39%)
Streaming Delayed Price Updated: 12:50 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 Next >
11 Analysts Have This To Say About AtriCure
Via Benzinga
Earnings Scheduled For February 12, 2025
Via Benzinga
Expert Outlook: AtriCure Through The Eyes Of 5 Analysts
Via Benzinga
Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Navigating 6 Analyst Ratings For AtriCure
Via Benzinga
Analyst Ratings For AtriCure
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024
ATRC stock results show that AtriCure met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024
ATRC stock results show that AtriCure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Recap: AtriCure Q4 Earnings
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
AtriCure's Earnings: A Preview
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Where AtriCure Stands With Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About AtriCure
Via Benzinga
Analyst Ratings for AtriCure
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
Earnings Outlook For AtriCure
Via Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.